Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 1445

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 7A
Chunk 1445
---
  Cash ($)  
    Stock  Awards ($)  
    Stock  Option  Awards ($)(1)  
    Non-Equity  Incentive  Plan  Compensation ($)  
    Nonqualified  Deferred  Compensation  Earnings ($)  
    All Other  Compensation ($)  
    Total ($) 

    Todd Davis 
     14,396  
     52,258  
     299,215  
     —  
     20,000  
     —  
     385,869 

    Ezra Friedberg 
     14,396  
     26,111  
     149,608  
     —  
     20,000  
     —  
     210,115 

    Richard Malamut 
     14,396  
     26,111  
     149,608  
     —  
     20,000  
     —  
     210,115 

    Chia-Lin Simmons 
     14,396  
        
     183,675  
     —  
     20,000  
     —  
     218,071 

(1)
Amounts reflect the aggregate grant date fair value of the stock options granted to each named executive officer during the fiscal
year ended December 31, 2024 and 2023, as computed in accordance with Financial Accounting Standards Board ASC 718.

95 

Policies
and Practices Related to The Grant of Certain Equity Awards

We
maintain the 2023 Plan through which we grant equity awards, including stock options and stock appreciation rights, to our named
executive officers, other employees, and directors as part of our compensation program. In addition, certain employment agreements
with our named executive officers provide for the grant of such equity awards. We do not currently have a formal policy governing
the timing of grants of stock options, stock appreciation rights, or similar option-like instruments to named executive officers
or directors in relation to the release of material nonpublic information. Equity awards under the 2023 Plan have been granted
from time to time, including to directors to encourage their initial or continued service on our board of directors. Our board
of directors is evaluating the adoption of a policy concerning the timing of such awards relative to material non-public information
disclosures. We have not adopted any practice